Sacituzumab govitecan in breast cancer patients – an evaluation of progression-free survival, overall survival, and hypersensitivity reactions in real-world patients
Journal of Oncology Pharmacy Practice
Published online on February 16, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionSacituzumab govitecan is approved for the treatment of triple-negative advanced/metastatic breast cancer and hormone-receptor positive, HER2-negative advanced/metastatic breast cancer. Clinical trials show favorable improvements in progression-...
IntroductionSacituzumab govitecan is approved for the treatment of triple-negative advanced/metastatic breast cancer and hormone-receptor positive, HER2-negative advanced/metastatic breast cancer. Clinical trials show favorable improvements in progression-...